Tumor microenvironment denotes the non-cancerous cells and components presented in
the tumor, including molecules produced and released by them. The constant interactions …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

The tumor microenvironment is proposed to contribute substantially to the progression of
cancers, including breast cancer. Cancer‐associated fibroblasts (CAFs) are the most …

Although fibroblast heterogeneity is recognized in primary tumors, both its characterization
in and its impact on metastases remain unknown. Here, combining flow cytometry …

By providing spatial, molecular and morphological data over time, live-cell imaging can
provide a deeper understanding of the cellular and signalling events that determine cancer …

Over the past decade, immunotherapy has become a powerful and evident tool in the fight
against cancers. Notably, the rise of checkpoint blockade using monoclonal antibodies (anti …

Drug evaluation has always been an important area of research in the pharmaceutical
industry. However, animal welfare protection and other shortcomings of traditional drug …

Cancer immunotherapy has achieved remarkable success over the past decade by
modulating patients' own immune systems and unleashing pre-existing immunity. However …

Cancer heterogeneity has posed a great challenge to traditional cancer treatment, with the
reappearance of cancer heterogeneity of inter and intra patients being especially critical …

Metastasis is the main cause of cancer-related death owing to the blood-borne
dissemination of circulating tumor cells (CTCs) early in the process. A rare fraction of CTCs …